|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 154.70 EUR | +4.81% |
|
+13.67% | +30.00% |
| 02-13 | Genfit to Receive $20 Million Milestone Payment Linked to Sales of Ipsen's Iqirvo | MT |
| 02-13 | Ipsen Remains in the Green with UBS Support |  |
| Capitalization | 12.7B 15.07B 11.58B 11.06B 20.53B 1,365B 21.33B 135B 53.49B 659B 56.53B 55.37B 2,304B | P/E ratio 2025 |
22.4x | P/E ratio 2026 * | 16x |
|---|---|---|---|---|---|
| Enterprise value | 11.88B 14.1B 10.83B 10.34B 19.2B 1,277B 19.95B 126B 50.02B 617B 52.86B 51.77B 2,155B | EV / Sales 2025 |
2.49x | EV / Sales 2026 * | 2.86x |
| Free-Float |
41.56% | Yield 2025 * |
0.91% | Yield 2026 * | 0.85% |
Last Transcript: Ipsen
IPSEN Technically solid | 01-08 | BUY |
| 1 day | +4.81% | ||
| 1 week | +13.67% | ||
| Current month | +12.43% | ||
| 1 month | +21.33% | ||
| 3 months | +18.36% | ||
| 6 months | +40.76% | ||
| Current year | +30.00% |
| 1 week | 136.1 |  | 154.7 |
| 1 month | 130 | | 154.7 |
| Current year | 116 | | 154.7 |
| 1 year | 87.95 | | 154.7 |
| 3 years | 87.95 | | 154.7 |
| 5 years | 65.9 | | 154.7 |
| 10 years | 34.2 | | 155.95 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Loew
CEO | Chief Executive Officer | 58 | 01/07/2020 |
| Chief Executive Officer | 56 | 01/01/2020 | |
| Chief Tech/Sci/R&D Officer | 59 | 22/09/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Antoine Flochel
BRD | Director/Board Member | 61 | 30/08/2005 |
| Chairman | 67 | 22/11/2010 | |
Carol Xueref
BRD | Director/Board Member | 69 | 01/06/2012 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +2.71% | 0.43% | 150 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +4.81% | +13.67% | +37.02% | +48.18% | 15.07B | |
| +0.33% | -1.72% | +23.18% | +199.23% | 929B | |
| -0.45% | +1.44% | +55.91% | +50.24% | 587B | |
| +1.76% | +3.61% | +20.03% | +51.71% | 409B | |
| +0.08% | +1.01% | +20.89% | +28.94% | 374B | |
| +1.42% | +7.19% | +26.36% | +32.36% | 320B | |
| +1.08% | +4.32% | +27.98% | +55.61% | 311B | |
| +1.82% | -0.43% | +46.26% | +11.65% | 301B | |
| +1.32% | +5.11% | -45.12% | -37.51% | 219B | |
| +1.52% | -3.94% | +26.80% | +53.17% | 199B | |
| Average | +1.37% | +3.17% | +23.93% | +49.36% | 366.38B | |
| Weighted average by Cap. | +0.76% | +1.63% | +26.59% | +76.63% |
| 2025 | 2026 * | |
|---|---|---|
| Net sales | 3.77B 4.48B 3.44B 3.28B 6.1B 405B 6.33B 40.01B 15.88B 196B 16.78B 16.44B 684B | 4.07B 4.83B 3.71B 3.54B 6.58B 437B 6.83B 43.16B 17.13B 211B 18.11B 17.73B 738B |
| Net income | 711M 843M 648M 619M 1.15B 76.39B 1.19B 7.54B 2.99B 36.89B 3.16B 3.1B 129B | 818M 971M 747M 713M 1.32B 87.98B 1.37B 8.68B 3.45B 42.49B 3.64B 3.57B 148B |
| Net Debt | -824M -978M -752M -718M -1.33B -88.57B -1.38B -8.74B -3.47B -42.77B -3.67B -3.59B -149B | -1.07B -1.27B -973M -929M -1.72B -115B -1.79B -11.31B -4.49B -55.36B -4.75B -4.65B -193B |
Employees
5,358
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/02/26 | 154.70 € | +4.81% | 146,747 |
| 12/02/26 | 147.60 € | +6.34% | 227,404 |
| 11/02/26 | 138.80 € | -0.64% | 84,602 |
| 10/02/26 | 139.70 € | +1.31% | 93,908 |
| 09/02/26 | 137.90 € | +1.32% | 67,063 |
Sell
Buy
Mean consensus
HOLD
Number of Analysts
15
Last Close Price
154.70EUR
Average target price
138.53EUR
Spread / Average Target
-10.45%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- IPN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition